I love working with companies as they grow – learning about the work they do and getting to know the people who turn great ideas into reality.
About Katie
Katie Kazem's practice focuses on corporate and securities law and includes the general representation of both public and private companies, with particular experience in advising European life sciences companies on IPOs, capital raising, SEC compliance and corporate governance. She has experience working on M&A, public offerings and venture capital financings.
Representative company-side and underwriter-side public offerings:
- Valneva SE – $107.6 million IPO, $102.0 million follow-on offering
- Nanobiotix SA – $113.3 million IPO
- Genfit SA - $155.4 million IPO
- Innate Pharma SA - $79.1 million IPO
- MaxCyte, Inc. - $201.8 million IPO
- Renalytix plc - $74.3 million IPO
- Landos Biopharma – $100 million IPO
- 2U – $119.3 million IPO
- Aclaris Therapeutics – $105 million follow-on offering
- Autolus Therapeutics – $150 million IPO
- Biohaven Pharmaceuticals - $193.5 million IPO
- Clearside – aggregate $77.4 million IPO and follow-on offering
- Entasis Therapeutics – $75 million IPO
- Erytech – $125 million IPO
Education
George Mason University, Antonin Scalia Law School
JD, 2010, magna cum laude
George Mason University, School of Public Policy
MA, 2007
College of William & Mary
BA, 2003, Government, Monroe Scholar